Zejing Pharmaceutical announced that clinical research data and latest developments of the new drug Alveltamig independently developed by the company were presented at the 2025 Asian Annual Meeting of the European Society of Medical Oncology. In the phase II dose optimization clinical study of ZG006 monotherapy in patients with refractory advanced small cell lung cancer, the optimal remission rates for the 10 mg Q2W group and the 30 mg Q2W group were 60.0% and 66.7%, respectively. The confirmed remission rates were 53.3% and 56.7%, respectively, and the disease control rate was 73.3% for both groups; the median progression-free survival was 7.03 months and 5.59 months, respectively; the median duration of remission was immature. The 6-month dOR rate was 71.8% and 69.5%, respectively. 61.6% and 55.6%; the median survival time was immature. The 6-month OS rate was 83.2% and 76.7%, respectively, and the 12-month OS rate was 69.1% and 58.2%, respectively.

Zejing Pharmaceutical announced that clinical research data and latest developments of the new drug Alveltamig independently developed by the company were presented at the 2025 Asian Annual Meeting of the European Society of Medical Oncology. In the phase II dose optimization clinical study of ZG006 monotherapy in patients with refractory advanced small cell lung cancer, the optimal remission rates for the 10 mg Q2W group and the 30 mg Q2W group were 60.0% and 66.7%, respectively. The confirmed remission rates were 53.3% and 56.7%, respectively, and the disease control rate was 73.3% for both groups; the median progression-free survival was 7.03 months and 5.59 months, respectively; the median duration of remission was immature. The 6-month dOR rate was 71.8% and 69.5%, respectively. 61.6% and 55.6%; the median survival time was immature. The 6-month OS rate was 83.2% and 76.7%, respectively, and the 12-month OS rate was 69.1% and 58.2%, respectively.